Q2 saw 11% adjusted EPS growth and 5% organic sales growth, with strong performance in Life Sciences, Global High-Tech, and Food & Beverage. The outlook was raised for 2026, reaffirming a 20% operating margin target for 2027, as growth engines scale and portfolio mix shifts to higher-margin businesses.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.